Eton Pharmaceuticals Inc. (ETON)
NASDAQ: ETONHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ETON stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.76B
- P/E (TTM)
- 39.51
- Forward P/E
- 18.41
- EPS (TTM)
- $1.54
- Dividend yield
- None
- 52-week range
- 14.27 – 70.64
- Day range
- 59.18 – 61.65
- Volume / Avg
- 562.53K / 570.79K
- Beta
- —
- Shares outstanding
- 28.84M
52-week range
ETON stock today
Shares of Eton Pharmaceuticals (ETON) finished lower on Nov 20 at $60.85, a drop of 0.83% or $0.51 per share, versus the S&P 500's 3.70% decline. At this level, ETON sits near the top of its 52-week range of $14.27 to $70.64: 13.9% below the high, set on Nov 11, 2026 and 326.4% above the low. ETON is up 259.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 269.7%.
Eton Pharmaceuticals trades at 39.5x its trailing twelve-month earnings per share of $1.54. Its forward P/E of 18.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Eton Pharmaceuticals
Company profileEton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Sean E. Brynjelsen
- Headquarters
- Deer Park, IL
- Employees
- 44
- IPO year
- 2018
- Website
- etonpharma.com
Financial highlights
Full financialsIn fiscal 2025, Eton Pharmaceuticals generated $80.0 million in revenue, up 104.9% from fiscal 2024, its 3rd consecutive year of revenue growth. Eton Pharmaceuticals reported a net loss of $4.6 million, compared with a loss of $3.8 million a year earlier. Gross margin was 53.5% (down from 60.0%) and operating margin -1.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $79.95M | $39.01M | $31.64M | $21.25M | $21.83M |
| Growth | +104.94% | +23.29% | +48.90% | -2.66% | +55879.49% |
| Net income | $-4.60M | $-3.82M | $-936.00K | $-9.02M | $-1.96M |
| EPS (diluted) | — | — | — | — | $-0.08 |
Analyst forecast
ForecastConsensus (4 analysts)
strong_buy
Avg. price target
$80.75+32.70%
- Strong buy 0
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $1.06 vs $0.34
- Surprise
- +211.76%
ETON news
All ETON news- REGN Gets FDA Nod for Livsayis in Generalized Myasthenia GravisNasdaqREGN, ALNY, VCEL, ETON
- NVS Gets FDA Nod for Cosentyx in Adults With Polymyalgia RheumaticaNasdaqNVS, VCEL, ETON
- Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study ResultsNasdaq
- Eton Pharmaceuticals Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Eton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in LondonGlobeNewswire
- ETON Gears Up to Report Q3 Earnings: What Can Investors Expect?NasdaqETON, TGTX, IOVA, AMRX
- Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic SpasmsGlobeNewswire
- Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026GlobeNewswire
Eton Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| STOKStoke Therapeutics Inc. | 26.81 | -0.45% | $1.75B | vs ETON |
| TRAXFirst Tracks Biotherapeutics Inc. | 41.64 | -6.34% | $1.75B | vs ETON |
| ZYMEZymeworks Inc. | 26.14 | -2.68% | $1.81B | vs ETON |
| MRVIMaravai LifeSciences Holdings Inc. Class A | 6.98 | -2.92% | $1.81B | vs ETON |
| SDGRSchrodinger Inc. | 22.93 | -12.95% | $1.72B | vs ETON |
| KRSAKorsana Biosciences Inc. | 37.56 | +5.95% | $1.71B | vs ETON |
| SEPNSepterna Inc. | 38.61 | -1.51% | $1.84B | vs ETON |
| VERAVera Therapeutics Inc. Class A | 25.45 | -4.86% | $1.84B | vs ETON |
Indexes, lists and sector
Eton Pharmaceuticals stock FAQ
What is Eton Pharmaceuticals's stock price today?
ETON last traded at $60.85 as of Nov 20, 4:00 PM EST, down 0.83% on the day. Prices are delayed at least 15 minutes.
What is ETON's P/E ratio?
ETON trades at a trailing P/E ratio of 39.51 and a forward P/E of 18.41.
Who is Eton Pharmaceuticals's CEO?
Mr. Sean E. Brynjelsen is the chief executive officer of Eton Pharmaceuticals Inc., which has about 44 employees.
What is the ETON 52-week high?
The 52-week high for ETON is $70.64 and the 52-week low is $14.27. The stock is currently 13.9% below its high.